Back to today’s briefing

Story perspectives

New RUFY1-RET Mutation Reveals Drug Resistance in Lung Cancer

2/7/2025

33 4

Summary

Story summary

A groundbreaking case report uncovers the RUFY1-RET fusion mutation, a significant player in drug resistance for a non-small cell lung cancer patient. After initially responding to lorlatinib, the patient's health deteriorated within six months. This discovery underscores the critical need for advanced genetic testing and continuous research to combat the ever-changing landscape of cancer treatment.

1 of 1

Story summary

A groundbreaking case report uncovers the RUFY1-RET fusion mutation, a significant player in drug resistance for a non-small cell lung cancer patient. After initially responding to lorlatinib, the patient's health deteriorated within six months. This discovery underscores the critical need for advanced genetic testing and continuous research to combat the ever-changing landscape of cancer treatment.